Allison Pike

451 total citations
9 papers, 93 citations indexed

About

Allison Pike is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Allison Pike has authored 9 papers receiving a total of 93 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 6 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Allison Pike's work include Acute Myeloid Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Allison Pike is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Allison Pike collaborates with scholars based in United States. Allison Pike's co-authors include Hagop M. Kantarjian, Elias Jabbour, Naval Daver, Srđan Verstovšek, Naveen Pemmaraju, Lingsha Zhou, Xuemei Wang, Prithviraj Bose, Guillermo Garcia‐Manero and Courtney D. DiNardo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Lymphoma Myeloma & Leukemia.

In The Last Decade

Allison Pike

8 papers receiving 93 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Allison Pike United States 6 82 57 52 18 11 9 93
Benoît De Renzis France 5 117 1.4× 89 1.6× 67 1.3× 29 1.6× 14 1.3× 15 138
Shouryadeep Srivastava United States 8 67 0.8× 55 1.0× 38 0.7× 27 1.5× 9 0.8× 17 106
Anne-Marie Watson Australia 5 109 1.3× 35 0.6× 48 0.9× 44 2.4× 13 1.2× 12 137
Fausto Palmieri Italy 2 41 0.5× 57 1.0× 42 0.8× 20 1.1× 6 0.5× 5 75
Emilio Usala Italy 5 59 0.7× 82 1.4× 47 0.9× 26 1.4× 5 0.5× 6 104
Souria Dougherty United States 6 75 0.9× 73 1.3× 54 1.0× 17 0.9× 5 0.5× 21 102
Ricardo Delumpa United States 5 70 0.9× 25 0.4× 34 0.7× 4 0.2× 14 1.3× 8 79
Ghayas C. Issa United States 6 132 1.6× 28 0.5× 92 1.8× 10 0.6× 31 2.8× 27 156
Xénia Cabagnols France 3 30 0.4× 36 0.6× 60 1.2× 9 0.5× 3 0.3× 3 74
Astghik Voskanyan Germany 3 62 0.8× 48 0.8× 9 0.2× 17 0.9× 19 1.7× 9 71

Countries citing papers authored by Allison Pike

Since Specialization
Citations

This map shows the geographic impact of Allison Pike's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Pike with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Pike more than expected).

Fields of papers citing papers by Allison Pike

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Pike. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Pike. The network helps show where Allison Pike may publish in the future.

Co-authorship network of co-authors of Allison Pike

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Pike. A scholar is included among the top collaborators of Allison Pike based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Pike. Allison Pike is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Maiti, Abhishek, Courtney D. DiNardo, Maro Ohanian, et al.. (2023). Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia. Blood. 142(Supplement 1). 4289–4289. 2 indexed citations
2.
Yılmaz, Musa, Hagop M. Kantarjian, Muharrem Müftüoğlu, et al.. (2021). Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML).. Journal of Clinical Oncology. 39(15_suppl). e19019–e19019. 9 indexed citations
3.
4.
Guerra, Veronica, Hagop M. Kantarjian, Gautam Borthakur, et al.. (2019). A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib. Blood. 134(Supplement_1). 5906–5906. 7 indexed citations
5.
Bose, Prithviraj, Naval Daver, Naveen Pemmaraju, et al.. (2017). Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia. Blood. 130. 255–255. 21 indexed citations
6.
Jain, Nitin, Farhad Ravandi, Guillermo Garcia‐Manero, et al.. (2016). Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 128(22). 2817–2817. 2 indexed citations
7.
Bose, Prithviraj, Naval Daver, Elias Jabbour, et al.. (2016). Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood. 128(22). 478–478. 24 indexed citations
8.
9.
DiNardo, Courtney D., Guilin Tang, Naveen Pemmaraju, et al.. (2014). Acute Myeloid Leukemia With t(10;11): A Pathological Entity With Distinct Clinical Presentation. Clinical Lymphoma Myeloma & Leukemia. 15(1). 47–51. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benoît De Renzis Breakdown of academic impact, for papers by Shouryadeep Srivastava Breakdown of academic impact, for papers by Anne-Marie Watson Breakdown of academic impact, for papers by Fausto Palmieri Breakdown of academic impact, for papers by Emilio Usala Breakdown of academic impact, for papers by Souria Dougherty Breakdown of academic impact, for papers by Ricardo Delumpa Breakdown of academic impact, for papers by Ghayas C. Issa Breakdown of academic impact, for papers by Xénia Cabagnols Breakdown of academic impact, for papers by Astghik Voskanyan
Rankless by CCL
2026